Vinva Investment Management Boosts Zimmer Biomet Holdings Stake

Hedge fund increases position in medical device company by over 785% in Q3

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd. significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the third quarter, according to a recent SEC filing. The hedge fund now owns 110,759 shares of the medical equipment provider's stock, up from just 12,514 shares in the prior quarter - a 785.1% increase.

Why it matters

Zimmer Biomet is a major player in the orthopedic and musculoskeletal healthcare industry, so increased investment from a hedge fund like Vinva could signal confidence in the company's future performance and growth prospects. This news provides insight into the investment strategies of institutional investors and may influence how other funds and analysts view Zimmer Biomet's stock.

The details

According to the filing, Vinva Investment Management purchased an additional 98,245 shares of Zimmer Biomet during Q3, bringing its total stake to 110,759 shares worth approximately $10.9 million. This represents about 0.06% ownership in the company. The increased investment comes as Zimmer Biomet's stock has seen some volatility, with the share price ranging between $84.59 and $114.44 over the past 52 weeks.

  • Vinva Investment Management increased its Zimmer Biomet holdings during the third quarter of 2026.
  • Zimmer Biomet's stock has traded between $84.59 and $114.44 over the past 52 weeks.

The players

Vinva Investment Management Ltd

A hedge fund that significantly increased its stake in Zimmer Biomet Holdings, Inc. during the third quarter of 2026.

Zimmer Biomet Holdings, Inc.

A global medical device company focused on musculoskeletal healthcare, headquartered in Warsaw, Indiana.

Got photos? Submit your photos here. ›

The takeaway

Vinva Investment Management's substantial increase in its Zimmer Biomet holdings suggests the hedge fund sees strong potential in the medical device company's future performance, despite recent stock price volatility. This development provides insight into how institutional investors view Zimmer Biomet's prospects within the broader orthopedics and musculoskeletal healthcare market.